In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Esperion, Again: Pfizer's First Spin-Out's Familiar Look

Executive Summary

This examination of Pfizer's first foray into spin-outs is a sidebar to "Can Out-Partnering Power Pfizer Over the "Second Cliff?"" Pfizer's Esperion spin-out hopes to pick up where it left off five years ago when Pfizer bought its first incarnation: developing HDL-raising therapies for CV disease.
Advertisement

Related Content

Conatus Acquires Idun's Assets
The GSK/Pfizer HIV Venture: Another Sign of Change?
Pfizer Restructures for a More Flexible Future
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2008
Can Out-Partnering Help Vault Pfizer Over the "Second Cliff"?
Can Out-Partnering Help Vault Pfizer Over the "Second Cliff"?
Best Laid Plans: Pfizer's Torcetrapib Tanks
Best Laid Plans: Pfizer's Torcetrapib Tanks
A Recipe for Acquisition: the Esperion Strategy
A Recipe for Acquisition: the Esperion Strategy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003117

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel